Prediqtus, LLC is the pre-eminent patent advisory and commercialization advisory service in the biotechnology and medical device spaces.
Established in 2012 as IP Shakti, Prediqtus is a patent monetization advisory service with a passion to discover assets which can bring significant value to corporations of all sizes, universities, and federal laboratories. Prediqtus uses a proprietary and intelligent Patent Analytics platform that is not commercially available, in effect saving significant resources upfront. Prediqtus provides customized Patent Advisory, Transactions, and Patent Valuation services to its fortune 500 clients as well as prominent universities around the world. Prediqtus provides the right blend of technology expertise and strategy to its clients. All work performed at Prediqtus is done by engaged, experienced professionals. Prediqtus is a think tank which provides consulting services for creation of new IP marketplaces. By integrating patent monetization and analytics with business development strategy, the experts at Prediqtus can produce significant value. Prediqtus was formed as a world class Proof of Concept model for medical devices in partnership with leading universities around the world. Utilizing robust CEOs in Residence (CIR) program and Entrepreneurs in Residence (EIR), Prediqtus spins out viable startup companies. They play an integral role in unlocking innovation by providing early-stage support to begin the commercialization process. Although research is thriving, many valuable technologies fail to make it to market. This is especially disheartening in medical fields, as patients anxiously await new technology to improve their quality of life. Prediqtus understands the hurdles that universities, non-profits, and small entities face when deploying new innovations.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 5, 2013 | Grant | $150K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |